Carisma Therapeutics (CARM) Competitors $0.41 -0.01 (-3.33%) Closing price 03:58 PM EasternExtended Trading$0.42 +0.02 (+3.69%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. ABOS, PYXS, IGMS, INCR, IMUX, ICCC, BMEA, STRO, ADAP, and SKYEShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), IGM Biosciences (IGMS), InterCure (INCR), Immunic (IMUX), ImmuCell (ICCC), Biomea Fusion (BMEA), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Carisma Therapeutics vs. Its Competitors Acumen Pharmaceuticals Pyxis Oncology IGM Biosciences InterCure Immunic ImmuCell Biomea Fusion Sutro Biopharma Adaptimmune Therapeutics Skye Bioscience Carisma Therapeutics (NASDAQ:CARM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Which has more risk and volatility, CARM or ABOS? Carisma Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Do analysts prefer CARM or ABOS? Carisma Therapeutics currently has a consensus price target of $1.93, indicating a potential upside of 374.14%. Acumen Pharmaceuticals has a consensus price target of $6.33, indicating a potential upside of 443.63%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Carisma Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CARM or ABOS more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Acumen Pharmaceuticals N/A -58.24%-46.53% Do insiders & institutionals believe in CARM or ABOS? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor CARM or ABOS? In the previous week, Carisma Therapeutics had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Carisma Therapeutics and 1 mentions for Acumen Pharmaceuticals. Carisma Therapeutics' average media sentiment score of 0.00 equaled Acumen Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, CARM or ABOS? Carisma Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.86-$60.48M-$1.56-0.26Acumen PharmaceuticalsN/AN/A-$102.33M-$1.94-0.60 SummaryCarisma Therapeutics beats Acumen Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.55M$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-0.268.8627.4020.04Price / Sales0.86680.42419.46118.60Price / CashN/A157.0736.6357.47Price / Book-0.614.638.085.67Net Income-$60.48M$31.34M$3.16B$248.47M7 Day Performance-0.10%0.84%2.12%2.90%1 Month Performance128.47%7.92%4.43%5.75%1 Year Performance-70.79%1.87%35.62%21.36% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics1.8779 of 5 stars$0.41-3.3%$1.93+374.1%-70.8%$17.55M$19.63M-0.2620News CoverageGap DownABOSAcumen Pharmaceuticals1.3188 of 5 stars$1.23+2.5%$6.33+414.9%-50.2%$72.69MN/A-0.6320News CoveragePositive NewsPYXSPyxis Oncology1.2755 of 5 stars$1.21+3.4%$9.00+643.8%-59.2%$72.48M$16.15M-0.7660News CoveragePositive NewsIGMSIGM Biosciences4.3967 of 5 stars$1.16-0.9%$5.50+374.1%-79.4%$69.94M$2.68M-0.35190News CoverageINCRInterCure0.491 of 5 stars$1.52+0.3%N/A-27.8%$69.27M$66.28M0.00350Gap UpIMUXImmunic2.8721 of 5 stars$0.71-1.7%$11.60+1,538.4%-38.0%$68.99MN/A-0.5870Positive NewsICCCImmuCell0.317 of 5 stars$6.65-12.5%N/A+55.9%$68.68M$26.49M-94.9970News CoverageGap DownHigh Trading VolumeBMEABiomea Fusion2.9616 of 5 stars$1.69-6.6%$21.40+1,166.3%-62.8%$68.01MN/A-0.4850STROSutro Biopharma3.3476 of 5 stars$0.80-0.3%$6.11+665.4%-74.2%$67.64M$62.04M-0.27240ADAPAdaptimmune Therapeutics2.0816 of 5 stars$0.24-4.2%$1.52+526.4%-76.9%$67.06M$178.03M-0.90490SKYESkye Bioscience2.2745 of 5 stars$2.87+66.0%$16.60+478.2%-44.8%$66.90MN/A-3.5011 Related Companies and Tools Related Companies Acumen Pharmaceuticals Alternatives Pyxis Oncology Alternatives IGM Biosciences Alternatives InterCure Alternatives Immunic Alternatives ImmuCell Alternatives Biomea Fusion Alternatives Sutro Biopharma Alternatives Adaptimmune Therapeutics Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts